600276 恒瑞医药
已收盘 06-29 15:00:00
资讯
新帖
简况
恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症
智通财经 · 06-25
恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症
恒瑞医药子公司获NMPA批准 艾瑞利布注射液新适应症获批
美股速递 · 06-25
恒瑞医药子公司获NMPA批准 艾瑞利布注射液新适应症获批
恒瑞医药：HRS-4508片获临床试验批准
南方财经网 · 06-25
恒瑞医药：HRS-4508片获临床试验批准
恒瑞医药(01276)撤回艾玛昔替尼软膏的药品注册申请
智通财经 · 06-23
恒瑞医药(01276)撤回艾玛昔替尼软膏的药品注册申请
创新药概念集体上涨，恒瑞医药、三生制药涨超4%
格隆汇 · 06-23
创新药概念集体上涨，恒瑞医药、三生制药涨超4%
恒瑞医药：公司本期回购资金总额不低于人民币10亿元且不超过20亿元
证券日报 · 06-22
恒瑞医药：公司本期回购资金总额不低于人民币10亿元且不超过20亿元
恒瑞医药(600276.SH)：瑞维鲁胺片上市许可申请获EMA受理
智通财经 · 06-22
恒瑞医药(600276.SH)：瑞维鲁胺片上市许可申请获EMA受理
施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元
智通财经 · 06-17
施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元
恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股
智通财经 · 06-17
恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股
恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可
美股速递 · 06-16
恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可
恒瑞医药：HRS-7525片获临床试验批准
南方财经网 · 06-16
恒瑞医药：HRS-7525片获临床试验批准
2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相
恒瑞医药官微 · 06-11
2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相
恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参
每日经济新闻 · 06-11
恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参
恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股
智通财经 · 06-10
恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股
恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%
证券日报 · 06-09
恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%
恒瑞医药及子公司三款药物获批临床
财中社 · 06-09
恒瑞医药及子公司三款药物获批临床
恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股
智通财经 · 06-09
恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股
恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股
智通财经 · 06-08
恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
智通财经 · 06-05
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
智通财经 · 06-04
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":52.93,"timestamp":1782716400000,"preClose":48.67,"halted":0,"volume":172756167,"delay":0,"changeRate":0.0875,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"已收盘","change":4.26,"latestTime":"06-29 15:00:00","open":49.01,"high":53.31,"low":48.43,"amount":8959000000,"amplitude":0.1003,"askPrice":52.93,"askSize":55,"bidPrice":52.92,"bidSize":988,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782783000000},"marketStatusCode":5,"adr":0,"adjPreClose":48.67,"symbolType":"stock","openAndCloseTimeList":[[1782696600000,1782703800000],[1782709200000,1782716400000]],"highLimit":53.54,"lowLimit":43.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.52,"roa":"--","peRate":43.268209,"roe":"4.15%","epsLYR":1.19,"committee":-0.723867,"marketValue":351307000000,"turnoverRate":0.0271,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":58.15,"timestamp":1782720532001,"preClose":52.95,"halted":0,"volume":8489584,"delay":0,"premium":"-4.74"},"floatMarketCap":337641000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2646803381","title":"恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803381","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646803381?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:56","pubTimestamp":1782392219,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU1023057109.AUD","LU2097828805.USD","LU2097828557.USD","BK0183","BK0239","LU1580142542.USD","BK0060","LU1655091616.SGD","LU0359202008.SGD","LU1820825898.SGD","600276","LU1146622755.USD","LU0405327494.USD","LU1781817850.SGD","LU2289578879.USD","LU1997245177.USD","LU2328871848.SGD","LU2488822045.USD","LU2495084118.USD","LU0359201612.USD","LU2097828631.EUR","LU2543165471.USD","BK0028","LU2580892862.HKD","BK1191","LU1328615791.USD","LU2097828714.EUR","01276","LU1255011170.USD","BK0188","LU1997244956.HKD","BK0196","LU2580892789.USD","LU1064130708.USD","LU2097828474.EUR","BK0012","LU2148510915.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194506184","title":"恒瑞医药子公司获NMPA批准 艾瑞利布注射液新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1194506184","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194506184?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:48","pubTimestamp":1782391725,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司宣布，其子公司已收到国家药品监督管理局（NMPA）的通知，批准其艾瑞利布注射液增加新的适应症。这一进展标志着该药物在临床应用范围的进一步扩大，有望为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0183","BK0028","LU2580892789.USD","BK0239","LU1146622755.USD","600276","LU2289578879.USD","LU2097828805.USD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU1997245177.USD","BK1191","LU1255011170.USD","BK0012","LU0405327148.USD","LU2543165471.USD","LU2580892862.HKD","LU1820825898.SGD","LU0359201885.HKD","BK0188","LU2097828557.USD","LU1997244956.HKD","LU2097828714.EUR","LU2097828631.EUR","LU1655091616.SGD","LU2097828474.EUR","LU2488822045.USD","LU0359202008.SGD","LU1580142542.USD","LU1781817850.SGD","LU0359201612.USD","LU1328615791.USD","LU1064131003.USD","LU1064130708.USD","BK0196","LU1023057109.AUD","01276","LU2148510915.USD","LU0405327494.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874269","title":"恒瑞医药：HRS-4508片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874269","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646874269?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:47","pubTimestamp":1782384420,"startTime":"0","endTime":"0","summary":"南财智讯6月25日电，恒瑞医药公告，HRS-4508片收到国家药品监督管理局签发的《药物临床试验批准通知书》（受理号：CXHL2600335），同意开展晚期实体瘤的临床试验。该药为新型、高效、选择性酪氨酸激酶抑制剂，拟用于乳腺癌、肺癌等适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253783217493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU1255011170.USD","BK0239","BK0012","01276","LU2097828631.EUR","LU1997245177.USD","BK0028","600276","LU0359201885.HKD","LU0405327148.USD","LU1064131003.USD","LU1064130708.USD","LU1997244956.HKD","LU2148510915.USD","LU1655091616.SGD","BK0183","LU2495084118.USD","LU0359202008.SGD","LU2328871848.SGD","LU1820825898.SGD","BK0060","LU2580892789.USD","LU1328615791.USD","LU2097828557.USD","LU2580892862.HKD","BK1191","LU2543165471.USD","LU2097828474.EUR","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","LU2097828805.USD","LU1146622755.USD","LU1023057109.AUD","BK0188","LU1781817850.SGD","LU0405327494.USD","LU2289578879.USD","BK0196","LU1997245094.SGD","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645780833","title":"恒瑞医药(01276)撤回艾玛昔替尼软膏的药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2645780833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645780833?lang=zh_cn&edition=full","pubTime":"2026-06-23 19:29","pubTimestamp":1782214187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司收到国家药品监督管理局(以下简称“国家药监局”)签发的《药品注册申请终止通知书》，同意公司撤回艾玛昔替尼软膏的药品注册申请。艾玛昔替尼软膏是一种外用、高选择性的 JAK1 抑制剂，可通过高局部暴露更好地抑制 JAK1 信号传导，发挥抗炎和抑制免疫的生物学效应。公司同靶点片剂产品硫酸艾玛昔替尼片已于 2025 年 3 月获批上市，现已获批四个适应症，包括强直性嵴柱炎、特应性皮炎、类风湿关节炎和斑秃。本次撤回艾玛昔替尼软膏药品注册申请不会对公司当期及未来生产经营与业绩产生重大影响，公司将高效推进后续各项工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU2543165471.USD","LU2488822045.USD","LU1655091616.SGD","LU2289578879.USD","LU1255011170.USD","LU2148510915.USD","LU1781817850.SGD","LU1146622755.USD","LU2097828474.EUR","LU0405327148.USD","LU1997244956.HKD","BK0188","BK0028","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU1997245177.USD","BK0012","600276","BK0196","BK1191","LU1580142542.USD","LU0359201612.USD","LU1969619763.USD","LU1023057109.AUD","01276","LU1064131003.USD","LU1997245094.SGD","LU1328615791.USD","LU2580892789.USD","LU0359201885.HKD","LU2097828557.USD","LU2328871848.SGD","BK0239","LU2097828714.EUR","BK0060","BK0183","LU2097828631.EUR","LU2495084118.USD","LU0405327494.USD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004286","title":"创新药概念集体上涨，恒瑞医药、三生制药涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004286","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645004286?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:40","pubTimestamp":1782182400,"startTime":"0","endTime":"0","summary":"6月23日，港股创新药概念股集体上涨，其中，华昊中天医药、石四药集团涨超7%，康诺亚-B涨超5%，恒瑞医药、科伦博泰生物、康方生物、三生制药、晶泰控股涨超4%，歌礼制药-B、再鼎医药、信达生物、亚盛医药、乐普生物、百济神州、药明生物涨超3%。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\r\n 责任编辑：栎树","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2026/06/cms_20260623104000424.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/06/cms_20260623104000424.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/23104057544995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2097828714.EUR","LU1023057109.AUD","LU0359202008.SGD","LU1781817850.SGD","01530","BK0012","LU2148510915.USD","LU1969619763.USD","LU1997245177.USD","LU2097828474.EUR","LU1328615791.USD","BK1583","LU0359201612.USD","LU2495084118.USD","LU2580892789.USD","LU2580892862.HKD","06978","LU0405327494.USD","BK1161","BK0196","BK1191","01276","LU1064131003.USD","HK0000165453.HKD","LU0359201885.HKD","LU2328871848.SGD","BK0183","BK0028","LU2097828805.USD","LU2097828631.EUR","LU1146622755.USD","LU0405327148.USD","LU1655091616.SGD","LU1064130708.USD","BK0239","BK1593","BK0060","LU1255011170.USD","LU1997245094.SGD","LU2097828557.USD","BK0188","LU2289578879.USD","LU1997244956.HKD","LU1820825898.SGD","LU2543165471.USD","159992","600276","LU2488822045.USD","BK1574","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645302724","title":"恒瑞医药：公司本期回购资金总额不低于人民币10亿元且不超过20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645302724","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645302724?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:54","pubTimestamp":1782132840,"startTime":"0","endTime":"0","summary":"证券日报网讯6月22日，恒瑞医药在互动平台回答投资者提问时表示，公司本期回购资金总额不低于人民币10亿元且不超过20亿元，回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内。目前本次回购尚未结束，公司将在期限内继续进行回购，并根据回购股份事项进展情况及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223778312847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828805.USD","600276","BK0239","LU2148510915.USD","LU2495084118.USD","01276","BK0183","LU2580892789.USD","BK0196","LU1820825898.SGD","LU2289578879.USD","LU1064131003.USD","BK0060","LU2328871848.SGD","BK0028","LU2097828714.EUR","BK0188","LU2488822045.USD","LU1580142542.USD","LU1655091616.SGD","BK0012","LU2543165471.USD","LU2097828474.EUR","BK1191","LU1064130708.USD","LU0359201885.HKD","LU1997245094.SGD","LU1023057109.AUD","LU1969619763.USD","LU2097828631.EUR","LU1997245177.USD","LU0405327148.USD","LU0359201612.USD","LU1255011170.USD","LU2580892862.HKD","LU1781817850.SGD","LU0359202008.SGD","LU1997244956.HKD","LU1328615791.USD","LU2097828557.USD","LU0405327494.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞医药(600276.SH)：瑞维鲁胺片上市许可申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645409710?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到了欧洲药品管理局(European Medicines Agency，简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请，这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT)，治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","LU2580892862.HKD","LU2097828714.EUR","BK0028","BK0188","LU2495084118.USD","LU2488822045.USD","600276","EMA","LU2097828631.EUR","LU0405327494.USD","LU2097828474.EUR","BK0196","LU0359201612.USD","LU1580142542.USD","LU1655091616.SGD","LU1064131003.USD","LU1328615791.USD","LU2580892789.USD","LU0405327148.USD","LU1969619763.USD","LU1146622755.USD","LU2148510915.USD","LU2328871848.SGD","BK0060","LU2097828805.USD","BK0012","IPOS","LU1023057109.AUD","LU1064130708.USD","LU2097828557.USD","BK4081","LU1997245094.SGD","01276","LU2543165471.USD","LU1997245177.USD","LU0359202008.SGD","BK1191","LU1255011170.USD","BK0183","LU1781817850.SGD","LU1997244956.HKD","BK0239","LU2289578879.USD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745377","title":"施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644745377?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:43","pubTimestamp":1781696627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月12日，施罗德增持恒瑞医药(01276)94.88万股，每股作价54.5391港元，总金额约为5174.67万港元。增持后最新持股数目约为1320.22万股，持股比例为5.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU0405327494.USD","LU1146622755.USD","BK1191","LU2097828714.EUR","600276","LU2097828805.USD","01276","LU2495084118.USD","BK0196","LU2328871848.SGD","LU2488822045.USD","LU1997244956.HKD","BK0060","LU1997245177.USD","BK0239","LU0359201885.HKD","BK0183","LU2097828474.EUR","LU1064131003.USD","LU2543165471.USD","LU1580142542.USD","LU1820825898.SGD","LU0405327148.USD","LU1255011170.USD","LU2097828631.EUR","LU2289578879.USD","LU1969619763.USD","BK0188","LU1655091616.SGD","LU1023057109.AUD","LU2097828557.USD","LU0359202008.SGD","LU1064130708.USD","LU2580892789.USD","EWH","LU1328615791.USD","LU1997245094.SGD","BK0028","LU2148510915.USD","LU0359201612.USD","LU1781817850.SGD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644714982","title":"恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644714982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644714982?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:56","pubTimestamp":1781686567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月17日该公司斥资约人民币562.45万元回购12万股A股，回购价格为每股人民币46.85至46.88元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","LU1023057109.AUD","01276","BK0183","LU0359202008.SGD","LU2328871848.SGD","LU2580892789.USD","LU0359201612.USD","LU0359201885.HKD","LU1997245094.SGD","LU2097828474.EUR","LU0405327148.USD","399300","LU1064130708.USD","LU2580892862.HKD","LU0405327494.USD","LU1655091616.SGD","BK0028","LU1997245177.USD","LU1064131003.USD","LU1820825898.SGD","LU2148510915.USD","BK0012","600276","LU2097828631.EUR","LU2097828805.USD","LU2488822045.USD","BK0196","LU1328615791.USD","LU1781817850.SGD","LU1580142542.USD","BK0188","BK1191","159982","LU1146622755.USD","LU1255011170.USD","LU1969619763.USD","LU2097828557.USD","BK0239","LU2097828714.EUR","LU2495084118.USD","LU2289578879.USD","LU1997244956.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184570619","title":"恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1184570619","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184570619?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:33","pubTimestamp":1781616795,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其创新药物达匹昔利布伊塞酸盐片（一种CDK4/6抑制剂）已收到国家药品监督管理局（NMPA）关于新适应症的批准通知。这一进展标志着该药物在临床应用范围上的进一步拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201885.HKD","LU2580892862.HKD","LU2097828714.EUR","BK0028","BK0188","LU2495084118.USD","LU2488822045.USD","600276","LU2097828631.EUR","LU0405327494.USD","LU2097828474.EUR","BK0196","LU0359201612.USD","LU1580142542.USD","LU1655091616.SGD","LU1064131003.USD","LU1328615791.USD","LU2580892789.USD","LU0405327148.USD","LU1969619763.USD","LU1146622755.USD","LU2148510915.USD","LU2328871848.SGD","BK0060","LU2097828805.USD","BK0012","LU1064130708.USD","LU1023057109.AUD","LU2097828557.USD","LU1997245094.SGD","01276","LU2543165471.USD","LU1997245177.USD","LU0359202008.SGD","BK1191","LU1255011170.USD","BK0183","LU1781817850.SGD","LU1997244956.HKD","BK0239","LU2289578879.USD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643730703","title":"恒瑞医药：HRS-7525片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643730703","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643730703?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:03","pubTimestamp":1781600580,"startTime":"0","endTime":"0","summary":"南财智讯6月16日电，恒瑞医药公告，HRS-7525片收到国家药品监督管理局签发的《药物临床试验批准通知书》，审批结论为同意该药单药在晚期实体瘤中开展临床试验；受理号为CXHL2600319、CXHL2600320，申请事项为临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163773104428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU1580142542.USD","LU1997244956.HKD","BK0060","BK1191","BK0028","BK0183","LU1255011170.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2097828631.EUR","BK0196","01276","LU1781817850.SGD","LU1997245094.SGD","LU2488822045.USD","LU2580892789.USD","LU0359202008.SGD","LU2543165471.USD","LU1820825898.SGD","BK0012","LU1997245177.USD","LU1328615791.USD","LU1023057109.AUD","LU0359201612.USD","LU2097828474.EUR","LU1064131003.USD","LU0405327494.USD","LU2328871848.SGD","LU0359201885.HKD","LU1146622755.USD","LU0405327148.USD","LU2097828557.USD","LU1655091616.SGD","LU2289578879.USD","LU2097828714.EUR","LU1969619763.USD","BK0188","BK0239","LU1064130708.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642118285","title":"2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2642118285","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642118285?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:12","pubTimestamp":1781172720,"startTime":"0","endTime":"0","summary":"2026年欧洲抗风湿病联盟年会已于当地时间6月3日至6日在英国伦敦隆重召开。期间，恒瑞医药自主研发的IFNAR1/TACI抗体融合蛋白SHR-2173用于系统性红斑狼疮的一项多中心、开放标签、多剂量递增I期临床研究成果精彩亮相1。目前，针对上述任一通路的单靶点治疗均难以实现整体病情的有效控制。各组均无导致试验终止的TEAE。本研究的初步临床证据为SHR-2173的持续开发提供了重要依据。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-11/doc-iniaztwk5483464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0359201885.HKD","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU1023057109.AUD","LU2097828805.USD","LU2097828557.USD","BK0183","BK0239","LU1580142542.USD","BK0060","LU1655091616.SGD","LU0359202008.SGD","LU1820825898.SGD","TACI","600276","LU1146622755.USD","LU0405327494.USD","LU1781817850.SGD","LU2289578879.USD","LU1997245177.USD","LU2328871848.SGD","LU2488822045.USD","LU2495084118.USD","LU0359201612.USD","LU2097828631.EUR","LU2543165471.USD","BK0028","LU2580892862.HKD","BK1191","LU1328615791.USD","LU2097828714.EUR","01276","LU1255011170.USD","BK0188","LU1997244956.HKD","BK0196","LU2580892789.USD","LU1064130708.USD","LU2097828474.EUR","BK0012","LU2148510915.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642470626","title":"恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2642470626","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642470626?lang=zh_cn&edition=full","pubTime":"2026-06-11 09:31","pubTimestamp":1781141460,"startTime":"0","endTime":"0","summary":"截至6月10日收盘，市场全天震荡调整，沪深两市成交额2.62万亿元。医药ETF（512120）上涨1.53%，港股通生物科技ETF（159102）上涨1.40%。相关个股中，恒瑞医药上涨1.36%、药明康德上涨3.81%、片仔癀上涨0.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606113767626750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606113767626750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201885.HKD","BK1161","BK0060","159938","BK0183","LU2097828805.USD","09939","LU1997245177.USD","LU2580892862.HKD","LU1580142542.USD","LU1328615791.USD","LU1655091616.SGD","BK0012","BK1191","LU2097828557.USD","LU0405327494.USD","BK0188","01276","BK0028","LU1969619763.USD","LU1023057109.AUD","LU1820825898.SGD","BK1515","LU1781817850.SGD","LU1064131003.USD","600276","BK0239","LU2488822045.USD","LU2097828631.EUR","LU0359202008.SGD","LU0359201612.USD","BK0196","LU1997244956.HKD","LU1997245094.SGD","LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","LU1255011170.USD","LU2097828714.EUR","LU1146622755.USD","LU2289578879.USD","BK1574","LU0405327148.USD","LU2543165471.USD","LU2495084118.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442317","title":"恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442317","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442317?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:29","pubTimestamp":1781083796,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月10日，该公司斥资46.04万元回购1万股A股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU0405327494.USD","LU1146622755.USD","BK1191","LU2097828714.EUR","600276","LU2097828805.USD","01276","LU2495084118.USD","BK0196","LU2328871848.SGD","159982","LU2488822045.USD","LU1997244956.HKD","BK0060","LU1997245177.USD","BK0239","LU0359201885.HKD","BK0183","LU2097828474.EUR","LU1064131003.USD","LU2543165471.USD","LU1580142542.USD","LU1820825898.SGD","LU0405327148.USD","LU1255011170.USD","LU2097828631.EUR","399300","LU2289578879.USD","LU1969619763.USD","BK0188","LU1655091616.SGD","LU1023057109.AUD","LU2097828557.USD","LU0359202008.SGD","LU1064130708.USD","LU2580892789.USD","LU1328615791.USD","LU1997245094.SGD","BK0028","LU2148510915.USD","LU0359201612.USD","LU1781817850.SGD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642679744","title":"恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642679744","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642679744?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:54","pubTimestamp":1781006040,"startTime":"0","endTime":"0","summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司始终高度重视全体股东利益，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。（1）公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765312960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642466820","title":"恒瑞医药及子公司三款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2642466820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642466820?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:25","pubTimestamp":1780997100,"startTime":"0","endTime":"0","summary":"6月9日，恒瑞医药（600276/01276）发布公告，公司及子公司山东盛迪医药有限公司、广东恒瑞医药有限公司近日收到HRS-6209胶囊、HRS-8080片、HRS-9813胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765192426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU2097828805.USD","LU1064130708.USD","600276","LU1781817850.SGD","BK0028","LU2328871848.SGD","LU1146622755.USD","LU0359202008.SGD","LU2495084118.USD","LU2543165471.USD","BK0183","BK0196","BK1191","BK0012","LU0359201885.HKD","LU1820825898.SGD","LU2097828631.EUR","BK0239","LU0359201612.USD","LU0405327494.USD","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU0405327148.USD","LU2580892862.HKD","LU1997244956.HKD","LU1997245177.USD","LU1969619763.USD","LU1328615791.USD","LU2148510915.USD","LU1655091616.SGD","LU1997245094.SGD","LU1580142542.USD","LU2580892789.USD","LU1255011170.USD","01276","LU2097828474.EUR","BK0188","LU1023057109.AUD","LU2289578879.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146314","title":"恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642146314?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:49","pubTimestamp":1780994962,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月9日，该公司斥资人民币319.36万元回购7万股A股股份，每股回购价人民币45.3-45.82元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU2097828631.EUR","BK0060","LU1997245177.USD","LU1580142542.USD","LU1655091616.SGD","LU2543165471.USD","LU1064130708.USD","LU2097828474.EUR","LU2097828714.EUR","BK0012","LU2148510915.USD","399300","LU2289578879.USD","LU2495084118.USD","LU1820825898.SGD","LU0359201612.USD","LU2488822045.USD","BK0028","LU0359202008.SGD","LU1781817850.SGD","LU1146622755.USD","LU2580892862.HKD","LU1023057109.AUD","LU1328615791.USD","BK0239","BK1191","01276","BK0188","LU1997244956.HKD","LU0359201885.HKD","LU1064131003.USD","LU0405327494.USD","LU1997245094.SGD","LU2097828557.USD","BK0183","LU2097828805.USD","LU2328871848.SGD","LU1969619763.USD","LU0405327148.USD","LU1255011170.USD","LU2580892789.USD","159982","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641029491","title":"恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641029491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641029491?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:21","pubTimestamp":1780906880,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月8日，该公司斥资2042.57万元回购44.4万股A股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","LU1820825898.SGD","01276","LU1255011170.USD","LU1969619763.USD","LU1064131003.USD","BK0196","LU1064130708.USD","LU1655091616.SGD","LU2097828714.EUR","LU2328871848.SGD","LU2148510915.USD","LU1328615791.USD","BK0012","BK0188","LU1580142542.USD","BK1191","LU2097828631.EUR","600276","BK0060","LU2097828474.EUR","LU2543165471.USD","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","LU2580892789.USD","LU0405327494.USD","LU2097828557.USD","LU2097828805.USD","BK0183","BK0028","LU2289578879.USD","LU1997245094.SGD","LU2580892862.HKD","LU0359201612.USD","LU0359202008.SGD","LU1146622755.USD","LU0359201885.HKD","399300","159982","BK0239","LU2495084118.USD","LU0405327148.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641619989","title":"港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641619989","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641619989?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624500,"startTime":"0","endTime":"0","summary":"消息面上，据恒瑞医药官微消息，近日，在ASCO 2026年会上，公司创新药“双艾”组合联合经动脉化疗栓塞术对比单纯TACE治疗不可切除肝细胞癌的全国多中心、随机对照、III期研究亮相口头报告环节。该研究为这一“TACE联合靶免”治疗策略在uHCC中的应用提供了有力的循证支持。基于该研究，“双艾”组合联合TACE治疗不可切除的肝细胞癌的上市许可申请已于2026年年初获国家药监局受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU1997244956.HKD","BK0028","01276","BK0183","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","LU0405327148.USD","LU2495084118.USD","LU0359201885.HKD","BK4588","LU2543165471.USD","LU1969619763.USD","BK0239","LU1781817850.SGD","BK0188","LU1064131003.USD","LU1655091616.SGD","LU2097828474.EUR","BK0196","LU1064130708.USD","LU1997245177.USD","LU2580892862.HKD","BK0060","LU1146622755.USD","VXUS","BK1191","LU0359202008.SGD","LU2289578879.USD","600276","LU1997245094.SGD","BK0012","LU0405327494.USD","BK4585","LU0359201612.USD","TACE","LU1820825898.SGD","LU2328871848.SGD","LU2580892789.USD","LU2097828805.USD","LU2148510915.USD","LU1255011170.USD","LU2097828714.EUR","LU1328615791.USD","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155910","title":"恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155910?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:18","pubTimestamp":1780564719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月4日，该公司斥资人民币1982.37万元回购42万股A股股份，每股回购价人民币46.7-47.7元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1580142542.USD","LU1997244956.HKD","BK0060","BK1191","BK0028","BK0183","LU1255011170.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2097828631.EUR","BK0196","01276","LU1781817850.SGD","159982","LU1997245094.SGD","LU2488822045.USD","LU2580892789.USD","LU0359202008.SGD","LU2543165471.USD","LU1820825898.SGD","BK0012","LU1997245177.USD","LU1328615791.USD","LU1023057109.AUD","LU0359201612.USD","LU2097828474.EUR","LU1064131003.USD","LU0405327494.USD","LU2328871848.SGD","LU0359201885.HKD","LU1146622755.USD","LU0405327148.USD","LU2097828557.USD","LU1655091616.SGD","LU2289578879.USD","LU2097828714.EUR","LU1969619763.USD","BK0188","399300","BK0239","LU1064130708.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782740178007,"stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.1144},{"period":"6month","weight":-0.1997},{"period":"1year","weight":-0.0616},{"period":"ytd","weight":-0.1796}],"compareEarnings":[{"period":"1week","weight":-0.0155},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.029},{"period":"6month","weight":0.016},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}